Concepedia

Hadas Shasha‐Lavsky

HS

Statistics

Publications

9

Citations

935

H-Index

9

Active since

2015

Affiliations

Western Galilee Hospital(Current)

Shaare Zedek Medical Center

Alnylam Pharmaceuticals (United States)

Hospices Civils de Lyon

Rambam Health Care Campus

Hadas Shasha‐Lavsky is an author at Western Galilee Hospital specializing in renal disease, renal pathophysiology, and renal impairment.

ORCID

Publications per year

2015–2024

9

Publications

9

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 495 citations · Full text

, , +10

Treatment and long-term outcome in primary distal renal tubular acidosis

Sergio Camilo Lopez-Garcia, Francesco Emma, Stephen B. Walsh et al. · Nephrology Dialysis Transplantation · 2018 · 125 citations · Full text

, , +14

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

Mini Michael, Jaap W. Groothoff, Hadas Shasha‐Lavsky et al. · American Journal of Kidney Diseases · 2022 · 81 citations · Full text

, , +11

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children

David J. Sas, Daniella Magen, Wesley Hayes et al. · Genetics in Medicine · 2021 · 74 citations · Full text

, , +15

Chronic health conditions in Jewish Holocaust survivors born during World War II.

Lital Keinan‐Boker, Hadas Shasha‐Lavsky, Sofia Eilat-Zanani et al. · PubMed · 2015 · 49 citations

, , +14

1–5 of 9